Carbestrol
Clinical data
Other namesNSC-19962; ORF-2166
ATC code
  • None
Identifiers
  • 3-Ethyl-4-(4-methoxyphenyl)-2-methylcyclohex-3-ene-1-carboxylic acid
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC17H22O3
Molar mass274.360 g·mol−1
3D model (JSmol)
  • CCC1=C(CCC(C1C)C(=O)O)C2=CC=C(C=C2)OC
  • InChI=1S/C17H22O3/c1-4-14-11(2)15(17(18)19)9-10-16(14)12-5-7-13(20-3)8-6-12/h5-8,11,15H,4,9-10H2,1-3H3,(H,18,19)
  • Key:VJKVHUZOVAWKEB-UHFFFAOYSA-N

Carbestrol (developmental code names NSC-19962, ORF-2166) is a synthetic, nonsteroidal estrogen of the cyclohexenecarboxylic acid group and seco analogue of doisynolic acid that was described in the literature in 1956 and developed for the treatment of prostate cancer in the 1960s but was never marketed.[1][2][3][4]

See also

References

  1. ^ Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 516–. ISBN 978-1-4757-2085-3.
  2. ^ Arduino LJ (July 1964). "Carbestrol (NSC-19962) Treatment of Patients with Prostatic Carcinoma-Preliminary Report". Cancer Chemotherapy Reports. 39: 67–75. PMID 14201278.
  3. ^ Kogler J, Hill G, Sedransk N, Cole DR, Weiss AJ, Wilson W (October 1972). "Phase II study of carbestrol (NSC-19962) in patients with solid tumors". Cancer Chemotherapy Reports. 56 (5): 641–647. PMID 4652590.
  4. ^ Kirk RE, Othmer DF (1980). Encyclopedia of chemical technology. Wiley. p. 672. ISBN 978-0-471-02065-3.
Categories